Cytotoxicity Clinical Trial
Official title:
Pulmonary and Systemic Effects of Exposure to Wood Smoke
This is study is to assess pulmonary and systemic effects of exposure to wood smoke. Healthy volunteers will be expose under two different occasion to wood smoke and filtered air under two separated occasions with an interval of 3 weeks in-between. The aim of this study was to determine whether exposure to wood smoke from incomplete combustion would elicit airway inflammation in humans.
Brief Summary This is study is to assess pulmonary and systemic effects of exposure to wood
smoke. Healthy volunteers will be expose under two different occasion to wood smoke and to
filtered air for two hours under two separated occasions with an interval of 3 weeks
in-between. The aim of this study was to determine whether exposure to wood smoke from
incomplete combustion would elicit airway inflammation in humans.
Detailed description Air pollution is associate with increased pulmonary and cardiovascular
mobility and mortality. UNICEF recently published a report highlighting the health effects of
air pollution from a global perspective, with particular focus on pediatrics population.
Overall, air pollution is estimated to cause about 7 million deaths each year in the world,
of which about 600,000 of these apply to children under 5 years (1). Indoor and outdoor air
pollutants are the 3rd and 9th most common cause of death. Nearly 3 billion people are
dependent on biomass for daily needs, Exposure to wood smoke has been linked to elevated
asthma prevalence, increased asthma symptoms in children and adults, as well as higher
hospital admissions due to asthma attacks. The association between long-term indoor wood
smoke exposure and the development and worsening of chronic obstructive pulmonary disease has
been shown to be strong in many epidemiological studies (2,3), and the risk for chronic
obstructive pulmonary disease development has been estimated to be more than doubled for
solid fuel smoke compared with smoke from other types of fuels (4). Exposure to smoke from
combustion of wood and other biomass fuels has also been shown to increase the risk for acute
and chronic lower respiratory tract infections, including pneumonias and tuberculosis. The
aim of the current study was to further characterize the respiratory and systemic effects of
exposure to wood smoke emitted from incomplete soot-rich combustion in a wood stove.
The study will be performed in a randomized, double blind, crossover fashion. Twenty healthy
subjects will be exposed on two occasions, under well-controlled situations, to filtered air
and wood smoke in an exposure chamber at Thermochemical Energy Conversion Laboratory at Umeå
University. The chamber is made of stainless steel, has a volume of a 15.3 m3 and an air
exchange rate of around three times per hour and has been previously described (5). The mean
particle mass concentration of wood smoke will be 450 μg/m3. The exposures will last for two
hours, during which the subject will perform intermittent exercise on a bicycle ergometer,
alternate with rest at 15-minute intervals, to achieve an average minute ventilation of 20
L/min/m2 body surface. During the exposures, symptoms well be recorded according to the
modified Borg scale, as described previously (6). Spirometry and impulse oscillometry system
(IOS) will be used to assess the lung function at baseline and immediately after each
exposure. Bronchoscopy will be performed 6 hours after each exposure. Differential cell
counts and soluble components will be analyzed in peripheral blood sampling at baseline and 6
hours after each exposure.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03309358 -
A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis
|
Phase 1 | |
| Recruiting |
NCT01837355 -
Modulation of Intestinal and Pulmonary Inflammation by Lactobacillus Diet Supplementation in Pediatric Cystic Fibrosis
|
N/A | |
| Terminated |
NCT04433546 -
Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).
|
Phase 2 | |
| Completed |
NCT01748838 -
Phase 1 Study Assessing the Safety and Tolerability of CTX-4430
|
Phase 1 |